Philadelphia, Pennsylvania Clinical Trials
A listing of Philadelphia, Pennsylvania clinical trials actively recruiting patient volunteers.
Found 101 clinical trials
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
IMC-F106C is an immune-mobilizing T cell receptor against cancer (ImmTAC ) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-F106C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer …
- 0 views
- 19 Feb, 2024
- +9 other locations
Reduced Radiation Dose and IR-impact on Coronary Calcium Quantification
Evaluation of reduced radiation dose iterative reconstruction reconstructions for calcium scoring compared to full dose filtered back projection reconstructions
- 0 views
- 19 Feb, 2024
- 1 location
Using Direct Brain Stimulation to Study Cognitive Electrophysiology
This project forms a multi-site research collaboration to carry out verbal and spatial memory experiments in patient volunteers to better understand the neural bases of human memory, employing direct electrical brain stimulation as a tool to study those dynamics and their relationship to memory performance.
- 0 views
- 19 Feb, 2024
- +5 other locations
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients
This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.
- 0 views
- 19 Feb, 2024
- 1 location
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
The purpose of this study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate …
- 0 views
- 19 Feb, 2024
- +10 other locations
Phase I Study in Advanced Malignancies
RDT aims to take advantage of the relatively safer toxicity profiles of both lower dose radiation therapy and systemic ALA to treat non-superficial lesions in a manner similar to photodynamic therapy. The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, …
- 0 views
- 19 Feb, 2024
- 1 location
Cyclosporine in Patients With Moderate COVID-19
Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.
- 0 views
- 19 Feb, 2024
- 1 location
Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)
Mucosal-dominant pemphigus vulgaris (mPV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals. This phase 1 study is being conducted to find the maximum tolerated dose and optimal fractionated infusion schedule of an investigational …
- 0 views
- 19 Feb, 2024
- 1 location
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients
This Phase 1 single-dose, dose-escalation study is an open label trial evaluating the safety of CPI-006, a humanized monoclonal antibody targeting the CD73 cell-surface ectonucleotidase, as immunotherapy for stable hospitalized mild or moderately symptomatic COVID-19 patients.
- 0 views
- 19 Feb, 2024
- +1 other locations
Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) Before and During Treatment With Ocrelizumab
This is an open-label, multicenter study that includes a main study for all participants enrolled and an optional cerebrospinal fluid (CSF) sub-study. Self-identified African American (AA) and Hispanic or Latin American (HA) participants with a diagnosis of relapsing multiple sclerosis (RMS) will be enrolled. The treating neurologist must make an …
- 0 views
- 19 Feb, 2024
- +30 other locations